Repurposing Clinically Safe Drugs for DNA Repair Pathway Choice

Study Background and Research Question

DNA double-strand breaks (DSBs) are among the most deleterious forms of genomic damage, arising both spontaneously from endogenous metabolic processes and exogenously via genotoxic agents such as ionizing radiation and chemotherapeutics. Efficient repair of DSBs is crucial for cell survival and genomic stability, with repair predominantly occurring through non-homologous end joining (NHEJ), microhomology-mediated end joining (MMEJ), and homology-directed repair (HDR). The advent of CRISPR-Cas9 genome editing allows for targeted induction of DSBs at specific loci, but controlling the pathway choice for DSB repair remains a major challenge. This precision is vital for applications in gene therapy, disease modeling, and synthetic lethality-driven cancer therapy. The referenced study (Macak et al., 2025) investigates whether clinically safe, FDA-approved drugs can be repurposed to modulate the balance between these repair pathways, thereby optimizing genome editing outcomes and exploiting vulnerabilities in cancer cells.

Key Innovation from the Reference Study

The major innovation lies in the systematic, high-throughput screening of more than 7,000 FDA-approved drugs to evaluate their ability to shift DSB repair outcomes in human induced pluripotent stem cells (hiPSCs). Rather than focusing solely on known DNA repair inhibitors, the study adopts a drug repurposing strategy to identify both enhancers and inhibitors of NHEJ, MMEJ, and HDR. This approach not only expands the toolkit for precision genome editing but also uncovers new therapeutic candidates for synthetic lethality—targeting cancer cells with repair deficiencies by inhibiting compensatory pathways. Importantly, the study links drug action to quantifiable editing outcomes, moving beyond theoretical predictions to practical, workflow-relevant results.

Methods and Experimental Design Insights

The screening workflow utilizes doxycycline-inducible Cas9-expressing 409B2 hiPSCs, enabling controlled induction of DSBs at the FRMD7 genomic locus. During editing, cells are treated with different drugs (one per well, n = 7,240), followed by recovery and assessment of cell survival via resazurin fluorescence. DNA is then extracted and sequenced to quantify repair pathway usage by analyzing indel patterns and precise edits. The experimental design allows for direct measurement of drug effects on the distribution of NHEJ, MMEJ, and HDR outcomes. The study further examines gene expression and protein function (notably ESR2 and AOX1) via knockdown experiments, elucidating their roles in modulating repair pathways and enabling synergistic modulation (e.g., combining ESR2 silencing with NHEJ inhibition for an average 4.6-fold HDR increase).

Core Findings and Why They Matter

The screen reveals that multiple clinically safe drugs selectively modulate DSB repair pathway choice. Some compounds increase HDR frequency, which is especially valuable for precise genome editing where restoration of wild-type alleles or accurate knock-ins is required. Others enhance or suppress NHEJ or MMEJ, influencing the prevalence of indels or larger deletions. The study also identifies drugs that induce synthetic lethality when either NHEJ or HDR is genetically or pharmacologically blocked, pointing to new precision medicine strategies for targeting repair-deficient tumors. Protein-level insights highlight ESR2 and AOX1 as regulators of key repair proteins such as ATM and 53BP1, offering further avenues for combinatorial interventions. Collectively, these results demonstrate that pathway choice can be rationally engineered using small molecules, advancing both basic research and translational applications such as CAR-T cell engineering and gene therapy (Macak et al., 2025).

Comparison with Existing Internal Articles

Several recent resources provide a complementary perspective on chemical modulation of DNA repair and calcium signaling. For instance, "Dantrolene Sodium Salt: Transforming Calcium Signaling Modulation" discusses how the ryanodine receptor antagonist dantrolene sodium salt enables high-confidence modulation of calcium-dependent processes relevant to genome editing and synthetic lethality. Likewise, "Dantrolene Sodium Salt: Precision RyR Antagonism in DNA Repair Research" focuses on the mechanistic interplay between calcium signaling and repair pathway choice, underscoring the translational potential of integrating ryanodine receptor antagonists into CRISPR workflows. These internal articles reinforce the central theme of the reference study: that pharmacological agents—including ryanodine receptor antagonists such as dantrolene sodium salt—can serve as precise modulators in genomic engineering, disease modeling, and synthetic lethality research.

Limitations and Transferability

Despite its breadth, the study has several limitations. First, the drug screen was conducted in a single hiPSC genetic background and at one genomic locus, so pathway effects may differ in other cell types, tissues, or genomic contexts. Second, while cell survival and indel outcomes provide robust primary readouts, off-target drug effects and long-term cellular consequences remain to be fully characterized. The platform also does not account for the impact of chromatin state or three-dimensional genome architecture on repair pathway choice. Finally, while several drug hits are immediately translatable, clinical application in gene therapy or precision oncology will require additional validation and toxicity testing. Nevertheless, the approach is highly transferable to other cell models, disease contexts, and genome engineering platforms.

Protocol Parameters

• Drug treatment window: Apply candidate drugs (e.g., pathway modulators) during or immediately prior to CRISPR-Cas9 editing to maximize effect on repair outcomes; specific concentrations and durations should be empirically optimized based on cell type and compound.
• Cas9 induction: Use doxycycline (1 μg/mL) to induce Cas9 expression in iCRISPR hiPSCs for controlled DSB induction at the target locus.
• Cell recovery period: Allow 24–48 hours post-editing in normal media before assessing survival and extracting DNA for sequencing.
• Resazurin assay: Employ resazurin fluorescence as a quantitative measure of cell viability following drug and editing treatments.
• Sequencing and analysis: Use Illumina-based amplicon sequencing to characterize indel profiles and assign repair pathway usage; analyze with dedicated bioinformatics pipelines for accurate quantification.

Why this cross-domain matters, maturity, and limitations

The study bridges the fields of small-molecule pharmacology and genome engineering. By leveraging clinically safe drugs to modulate DNA repair, researchers can enhance CRISPR precision, improve disease modeling accuracy, and design more effective synthetic lethality strategies for cancer therapy. However, the maturity of this approach is still at the preclinical or early translational stage, with key challenges remaining in cross-cell-type validation and long-term safety assessment.

Research Support Resources

For researchers seeking to modulate intracellular calcium signaling and explore its impact on DNA repair, Dantrolene, sodium salt (SKU B6329) from APExBIO offers a potent and well-characterized ryanodine receptor antagonist suitable for calcium signaling modulation, disease modeling, and genome editing research. Its high purity and robust QC data support its application in workflows that require precise control of calcium-dependent DNA repair processes, as described in both the reference study and supporting internal resources.